417 related articles for article (PubMed ID: 32863270)
1. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B reactivation and immune check point inhibitors.
Godbert B; Petitpain N; Lopez A; Nisse YE; Gillet P
Dig Liver Dis; 2021 Apr; 53(4):452-455. PubMed ID: 32921602
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
4. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors.
Shen J; Wang X; Wang N; Wen S; Yang G; Li L; Fu J; Pan X
Front Cell Infect Microbiol; 2023; 13():1179689. PubMed ID: 37197205
[TBL] [Abstract][Full Text] [Related]
5. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y
Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258
[TBL] [Abstract][Full Text] [Related]
7. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
Yoo S; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Yoo C; Ryoo BY; Choi J
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):898-907. PubMed ID: 34182151
[TBL] [Abstract][Full Text] [Related]
8. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
Gong WF; Zhong JH; Lu SD; Wang XB; Zhang QM; Ma L; Zhang ZM; Xiang BD; Li LQ
Oncotarget; 2017 Feb; 8(9):15047-15056. PubMed ID: 28122361
[TBL] [Abstract][Full Text] [Related]
9. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load.
Sohn W; Paik YH; Cho JY; Ahn JM; Choi GS; Kim JM; Kwon CH; Joh JW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Viral Hepat; 2015 Jun; 22(6):539-50. PubMed ID: 25377516
[TBL] [Abstract][Full Text] [Related]
10. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy.
Ziogas DC; Kostantinou F; Cholongitas E; Anastasopoulou A; Diamantopoulos P; Haanen J; Gogas H
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067316
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Xia Z; Zhang J; Chen W; Zhou H; Du D; Zhu K; Chen H; Meng J; Yang J
Infect Dis Poverty; 2023 Sep; 12(1):87. PubMed ID: 37736699
[TBL] [Abstract][Full Text] [Related]
12. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy.
Wu CJ; Chau GY; Lee IC; Huo TI; Su CW; Hou MC; Huang YH
J Formos Med Assoc; 2021 Aug; 120(8):1563-1571. PubMed ID: 33334659
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
Chang JI; Sinn DH; Cho H; Kim S; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Dig Dis Sci; 2022 Sep; 67(9):4565-4573. PubMed ID: 34800218
[TBL] [Abstract][Full Text] [Related]
14. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
15. HBV induced hepatocellular carcinoma and related potential immunotherapy.
Jia L; Gao Y; He Y; Hooper JD; Yang P
Pharmacol Res; 2020 Sep; 159():104992. PubMed ID: 32505833
[TBL] [Abstract][Full Text] [Related]
16. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X; Qin P; Wang Y; Zhang M; Cui H; Gao Q; Wang Z
Cancer Immunol Immunother; 2023 Feb; 72(2):385-395. PubMed ID: 35907016
[TBL] [Abstract][Full Text] [Related]
17. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
Huang G; Lai EC; Lau WY; Zhou WP; Shen F; Pan ZY; Fu SY; Wu MC
Ann Surg; 2013 Mar; 257(3):490-505. PubMed ID: 22868358
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
Li X; Zhong X; Chen ZH; Xing YF; Wu DH; Chen J; Ma XK; Lin Q; Wen JY; Wei L; Wang TT; Ruan DY; Lin ZX; Wu XY; Dong M
Asian Pac J Cancer Prev; 2014; 15(22):9635-41. PubMed ID: 25520081
[TBL] [Abstract][Full Text] [Related]
19. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma.
Huang L; Li J; Lau WY; Yan J; Zhou F; Liu C; Zhang X; Shen J; Wu M; Yan Y
J Gastroenterol Hepatol; 2012 Jan; 27(1):158-64. PubMed ID: 21871026
[TBL] [Abstract][Full Text] [Related]
20. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.
Viganò M; Bhoori S; Lampertico P; Donato MF; Iavarone M; Grossi G; Facciorusso A; Caccamo L; Rossi G; Colombo M; Mazzaferro V
Liver Int; 2015 Sep; 35(9):2187-93. PubMed ID: 25809541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]